Article Text

Download PDFPDF
Cannabidiol reduced frequency of convulsive seizures in drug resistant Dravet syndrome
  1. Yasmin Moore1,
  2. Robert Robinson2
  1. 1 Glasgow Royal Infirmary, Glasgow, UK
  2. 2 Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK
  1. Correspondence to Dr Robert Robinson, Department of Paediatric Neurology, Great Ormond Street Hospital, Great Ormond St, London WC1N 3JH, UK; robert.robinson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design

Design: Multinational double-blinded placebo-controlled trial.1 Patients randomised in 1:1 ratio to receive cannabidiol or placebo, in addition to stable antiepileptic treatment regime.

Study question

Setting: Twenty-three centres in Europe and USA.

Patients: Patients aged 2 years to 18 years with established diagnosis of Dravet syndrome having at least four convulsive seizures during the 28-day baseline period despite regular antiepileptic medication.

Intervention: Adjunctive cannabidiol or placebo oral solution at 20 mg per kilogram of body weight per day.

Primary outcome: Percentage change in median frequency of convulsive seizures per month.

Follow-up period: Outcome measured over a 14-week treatment period in comparison to a 4-week baseline period.

Patient follow-up: One hundred and eight (90%) completed the trial: 85% (52/61) in the …

View Full Text


  • Contributor YM provided abstract. RR provided the commentary.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.